Journal DOI 10.68956/dyh5-kwte

Creative Commons source reading · Parkinson’s disease and related disorders

Meta-analysis of the Parkinson's disease gut microbiome suggests alterations linked to intestinal inflammation.

Stefano Romano; George M Savva; Janis R Bedarf; Ian G Charles; Falk Hildebrand; Arjan Narbad

Originally published in NPJ Parkinson's disease · 2021-03-10

From the article

Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.

Abstract

The gut microbiota is emerging as an important modulator of neurodegenerative diseases, and accumulating evidence has linked gut microbes to Parkinson's disease (PD) symptomatology and pathophysiology. PD is often preceded by gastrointestinal symptoms and alterations of the enteric nervous system accompany the disease. Several studies have analyzed the gut microbiome in PD, but a consensus on the features of the PD-specific microbiota is missing. Here, we conduct a meta-analysis re-analyzing the ten currently available 16S microbiome datasets to investigate whether common alterations in the gut microbiota of PD patients exist across cohorts. We found significant alterations in the PD-associated microbiome, which are robust to study-specific technical heterogeneities, although differences in microbiome structure between PD and controls are small. Enrichment of the genera Lactobacillus, Akkermansia, and Bifidobacterium and depletion of bacteria belonging to the Lachnospiraceae family and the Faecalibacterium genus, both important short-chain fatty acids producers, emerged as the most consistent PD gut microbiome alterations.

Discussion

In recent years, several studies have analyzed the gut microbiome of PD patients reporting various degrees of alteration compared to healthy controls. We wanted to verify whether consistent changes in the gut microbiome of PD patients can be identified across studies, as often contrasting results have been reported. Hence, we performed a meta-analysis re-analyzing all publicly available 16S rRNA-gene amplicon datasets obtained by studies that compared PD patients with healthy controls, to offer a comprehensive and robust description of the PD-associated gut microbiome.

Editorial reading guide

  • Was the evidence cross-sectional, longitudinal or experimental?
  • How did the authors account for age, disease stage and differences among participants?